Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
SIBN gained 9.5% through August 25 as Q2 revenue rose 15%, adjusted EBITDA increased 178%, losses beat consensus, the physician base grew 19%, and management raised 2026 guidance.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Negative Cash Flow ⢠Ongoing Losses SIBN has exceptional liquidity and high gross margins, but persistent losses, negative free cash flow, rising debt, and a premium valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Support Holding ⢠Lower Highs ⢠Neutral RSI Support Level: $18.50â$18.60 Resistance Level: $19.20â$19.50 SIBN weakened over the last month, holding $18.50â$18.60 support but needing to reclaim $19.11 to signal recovery.
Sentiment & News
Key News Insights: ⢠Earnings Upgrades ⢠Momentum Potential ⢠Investor Conference SIBN's positive analyst revisions, momentum appeal, and upcoming Morgan Stanley conference suggest strengthening investor interest.
AI Summary
SI-BONE's high-margin, double-digit growth model is beginning to show operating leverage, but the investment hinges on proving that physician expansion converts into sustained positive free cash flow before its growth valuation becomes vulnerable; watch upcoming quarters for expense discipline and cash-flow breakeven.
Description
SI-BONE, Inc. is a medical device company that develops implantable products for musculoskeletal conditions affecting the sacropelvic anatomy in the United States and abroad. Its portfolio includes minimally invasive implants used in sacroiliac joint fusion and pelvic fracture repair, and it sells primarily through a direct sales force supplemented by distributors. The company was founded in 2008 and is based in Santa Clara, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 25 | Sep 1 | SIBN | SI-BONE, Inc. | SIBN gained 9.5% through August 25 as Q2 revenue rose 15%, adjusted EBITDA increased 178%, losses beat consensus, the physician base grew 19%, and management raised 2026 guidance. | Closed | -3.2% |